Effectiveness and safety of Yufengningxin for treating coronary heart disease angina

A protocol for a systematic review and meta-analysis

Chao Liu, PhD\textsuperscript{a,b}, Jing Bai, MD\textsuperscript{a,c}, Lanchun Liu, MD\textsuperscript{a,b}, Jialiang Gao, PhD\textsuperscript{a}, Jie Wang, PhD\textsuperscript{a,*}

1. Introduction

Coronary heart disease (CHD) angina, a common cardiovascular disease, is caused by coronary artery stenosis or spasm, which leads to myocardial ischemia and hypoxia.\textsuperscript{[1]} The characteristics of angina pectoris is recurrent deep chest pain, which could radiate to the patients shoulder, neck, or inner arm. Since the end of the last century, cardiovascular disease has become a leading cause of death among Chinese residents.\textsuperscript{[2]} At present, 11396,000 people in China suffer from CHD. The mortality rate of urban/rural residents reaches 115.32 per 100,000 and 122.04 per 100,000, respectively, and it shows an increasing trend year by year. Every year, nearly 910,000 patients receive percutaneous coronary intervention therapy.\textsuperscript{[3]} CHD seriously affects people's quality of life and puts a huge economic burden on society.\textsuperscript{[4]}

Nitrates are the most commonly used drugs for relieving angina pectoris. However, the use of nitrates has been found to have some side effects in clinical practice, such as dizziness, blushing, nausea, and loss of appetite.\textsuperscript{[5]} Therefore, to explore novel strategies for alleviating symptoms of angina, especially those with no obvious side effects, becomes an urgent task. Recently, a high-quality systematic review concluded that traditional Chinese medicine in the treatment of CHD might be effective in alleviating angina symptoms, abnormal myocardial perfusion and neurological deficits, and could be used as a complementary therapy for the treatment of CHD.\textsuperscript{[6]}

Yufengningxin (YFNX), which is extracted and processed from Radix Puerariae, is a commonly used Chinese patent medicine for the treatment of CHD. It has the functions of relieving spasm and relieving pain, enhancing brain and coronary blood flow, and improving angina symptoms. Because of its...
2.1. Eligible criteria for study selection

2.1.1. Types of studies. We will include all relevant randomized controlled trials (RCTs) regarding the application of YFNX to the treatment of CHD angina, with no limitation of the language and the type of publication.

2.1.2. Types of participants. By following the World Health Organization (WHO) diagnostic criteria for CHD, 2 kinds of CHD angina will be included, including stable angina pectoris (SAP) and unstable angina (UA). We will not consider the patients gender, age, ethnicity and region.

2.1.3. Types of interventions. The control group accepted conventional therapy, such as aspirin, clopidogrel, β-blockers, statins, calcium channel blockers, renin-angiotensin-aldosterone system blockers, nitrates, etc. And the intervention group took YFNX combined with conventional therapy. The various dosage forms of YFNX will be included, such as tablets, capsules, dripping pills, granules and so on. Its dosage and duration will not be limited. The study in which other Chinese medicines were dripping pills, granules and so on. It will be excluded.

2.1.4. Types of outcome measures

2.1.4.1. Primary outcomes. The primary outcomes will be the frequency and duration of angina attacks.

2.1.4.2. Secondary outcomes. The secondary outcomes will include clinical efficacy rate, the efficacy rate in an electrocardiogram, scores of TCM syndrome, blood pressure, low-density lipoprotein cholesterol, fibrinogen, haematocrit and adverse events.

2.2. Search methods for the identification of studies

2.2.1. Electronic searches. We will perform a systematic search of the relevant databases, including PubMed, Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journal Database (VIP) and Chinese Biomedical Literature Database (CBM), from their inception to November 1, 2020. The English search terms include YFNX, CHD, angina pectoris and RCTs. The detailed search strategy for PubMed is shown in Table 1, and similar terms will be used in the other databases.

2.2.2. Search for other resources. We will also retrieve grey documents and clinical trial registers, such as WHO International Clinical Trials Registry Platform (ICTRP), the Chinese Clinical Trial Register (ChiCTR) and the Clinical Trials, to supplement the electronic databases.

2.3. Data collection and analysis

2.3.1. Selection of studies. We will import all studies into Endnote X9 software. Two researchers (Chao Liu and Jing Bai) will independently extract the potentially eligible studies by screening the titles and abstracts in accordance with the inclusion criteria. After removing irrelevant and duplicate studies, they will further scan the full text to assess their eligibility. All studies selected by the researchers will be cross-checked, and if there are any disagreements, they will be discussed and solved by a third author (Jie Wang). The literature screening and selection processes will be performed in accordance with the PRISMA flow chart shown in Figure 1.

2.3.2. Data extraction and management. Two researchers (Chao Liu and Jing Bai) will independently extract and manage the data from the finally included studies according to the predefined data collection form. The form will include study ID, study characteristics (authors name, country, title, publication year, and so on), methodological information (randomization, allocation hiding, blinding, selective reporting, loss of follow-up...
and any other bias information), patients information (numbers, age, sex, diagnostic criteria, and baseline disease severity), interventions and comparisons (dosage form, dose, frequency, and duration), and outcomes (primary outcomes and secondary outcomes). If there is any unclear or missing information, the author of the original study will be consulted. Any disagreements will be solved through discussion.

2.3.3. Assessment of risk of bias in included studies. The Cochrane “risk of bias” tool will be used to evaluate the risk of bias in each included study by 2 independent authors. The main items include selection bias (random sequence generation, allocation concealment), performance bias, detection bias, attrition bias, reporting bias and other biases. According to the actual situation of the research, each bias is divided into 3 levels, including low risk, high risk, and unclear. If there are any disagreements in the assessment, we will reach a consensus by discussing and negotiating with a third author (Lanchun Liu).

2.3.4. Measures of treatment effect. We will use the mean difference (MD) and 95% confidence interval (CI) to analyze the continuous data. For the dichotomous data, the rate ratio (RR) and the 95% CI will be used to expressed the results.

2.3.5. Dealing with missing data. As for the missing or incomplete information in the included studies, we will contact the author to obtain the missing or incomplete information by
email or other means. If the information is not accessible, the impact of the missing data should be discussed, and we will only analyze the available data.

2.3.6. Assessment of heterogeneity. The $I^2$ test will be used to evaluate the statistical heterogeneity. If $I^2 \leq 50\%$, that means there is no significant heterogeneity among studies and a fixed-effects model should be used to calculate the effect size; otherwise, it means there exists significant heterogeneity.

2.3.7. Data synthesis and analysis. The RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark) will be used for data synthesis. If small heterogeneity ($I^2 \leq 50\%$) exists between the studies, the fixed-effects model will be used for meta-analysis. Conversely, if evident heterogeneity is found, a random-effects model will be applied to evaluate the outcome data, and a subgroup, sensitivity analysis or descriptive analysis will be conducted to analyze the potential reasons for heterogeneity. If quantitative synthesis is not appropriate, we will perform a descriptive analysis.

2.3.8. Publication bias. If there are more than 10 trials in the study, the funnel plot analysis will be performed to evaluate publication bias. In the case of fewer than 10 trials, we will conduct a quantitative analysis through the Egger test by using the STATA 14.0 software.

2.3.9. Subgroup analysis. If there are obvious heterogeneity and more than 10 trials among the included studies, a subgroup analysis based on the type of angina pectoris, the dosage form of YFNX and adverse events should be conducted.

2.3.10. Sensitivity analysis. To ensure the robustness of analytical conclusions, we need to perform a sensitivity analysis by eliminating each study individually or changing the category of the effect model.

2.3.11. Grading the quality of evidence. The GRADE tool[19] will be used to classify the quality of evidence in the systematic review into 4 levels: “high quality”, “moderate quality”, “low quality”, and “extremely low quality”.

2.3.12. Ethics and dissemination. This article collects published articles for data analysis and does not involve the individual privacy of patients, so ethical approval is not necessary. The results of this review will be presented at relevant conferences and published in peer-reviewed journals.

3. Discussion

CHD angina affects physical function and the quality of life, and imposes a broad burden on both patients and caregivers. YFNX has significant clinical effects, and its main active ingredient puerarin can protect myocardial ischemia/reperfusion injury by inhibiting inflammation[10] and autophagy via the Akt signaling pathway,[19] increasing superoxide dismutase, decreasing creatine kinase and methylene dioxyxanthemamine.[11] Therefore, we designed the systematic evaluation protocol by using the latest data to test the effectiveness and safety of YFNX in the treatment of CHD angina. It is hoped that this study could find more rigorous medical evidence for the application of YFNX to the treatment of CHD angina, thus providing a reference for clinical practice. However, there are still some potential limitations in this study. First, there still lacks of a high-quality, multi-center and large sample clinical trial, which will affect the authenticity of the evidence. Second, different dosage forms and doses of YFNX may lead to significant heterogeneity of results. Therefore, more rigorous, large-sample, high-quality RCTs should be carried out in future studies to confirm the clinical efficacy of YFNX.

Author contributions

Conceptualization: Chao Liu.
Data curation: Jing Bai, Lanchun Liu.
Formal analysis: Jing Bai, Jialiang Gao.
Funding acquisition: Jie Wang.
Methodology: Chao Liu, Lanchun Liu.
Project administration: Jie Wang.
Resources: Jing Bai.
Software: Lanchun Liu, Jialiang Gao.
Writing – original draft: Chao Liu, Lanchun Liu.
Writing – review & editing: Chao Liu, Jing Bai.

References

[1] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Europ Heart J 2013;34:2949–3003.
[2] Yichong L, Shiwei L, Xinying Z, et al. Report on burden of cardiovascular diseases from 1990 to 2016 in China. Chin Circulation J 2019;34:729–40.
[3] The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2019: an updated summary. Chin Circulation J 2020;35:833–34.
[4] Le C, Fang Y, Linxiong W, et al. Economic burden and cost determinants of coronary heart disease in rural southwest China: a multilevel analysis. Public Health 2015;129:68–73.
[5] Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139–228.
[6] Hao P, Jiang F, Cheng J, et al. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol 2017;69:2952–66.
[7] National Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China 2020 edition. 2020; Beijing: China Medical Science and Technology Press, 1800–01.
[8] Li Z, Fu XT, Guo HZ. Study on HPLC specific chromatogram of Yufeng Ningxin tablets. Chin J Pharm Anal 2012;32:2046–50.
[9] Zhang XQ, Zhou FR, Yan Y, et al. Determination of Puerarin in Radix Puerariae and Yufengningxin tablets by HPLC. China J Chin Materia Medica 1995;20:477–9.
[10] Wang Z, Chen R, Li J, et al. Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLPR3 inflammasome: the role of the SIRT1/NF-kB pathway. Intern Immunopharmacol 2020;89:107086.
[11] Wenjun H, Jing W, Tao L, et al. The protective effect of puerarin on Myocardial Infarction Reperfusion Injury (MIRI): a meta-analysis of randomized studies in rat models. Med Sci Monit 2015;21:1700–6.
[12] Zhou Y, Li M, Song J, et al. The cardioprotective effects of the new crystal form of puerarin in isoproterenol-induced myocardial ischemia rats based on metabolomics. Sci Rep 2020;10:17787.
[13] Chen H, Jia XB. Clinical study on Yufeng Ningxin Tablets combined with nifedipine in treatment of chronic stable angina pectoris. Drugs Clin 2019;34:3255–9.
[14] Lian LH, Xie G, Jing Y, et al. Yufeng Ningxin dropping pills for 60 cases of coronary heart disease. Modern J Integrated Tradit Chin Western Med 2011;20:2860.
[15] Chen J, Wang SM. Clinical study of Yufeng Ningxin Dipping Pills combined with tramizadine in treatment of coronary heart disease. Drugs Clin 2018;33:1371–5.
[16] Ye H, He MH. Clinical observation of Yufeng Ningxin dropping pill in treating hypertension with the syndrome of yin deficiency and yang hyperactivity. Chinese Traditi Herbal Drugs 2003;34:75–6.
[17] Lu XR, Zheng X, Zhu CJ. Protective effect of Yufengningxin capsule on animal model of ischemia and hypoxia injury. Res Pract Chin Med 2004;18:44–6.
[18] Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
[19] Guyatt G, Oxman A, Vist G, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
[20] Tang H, Song X, Ling Y, et al. Puerarin attenuates myocardial hypoxia/reoxygenation injury by inhibiting autophagy via the Akt signaling pathway. Mol Med Rep 2017;15:3747–54.